What We're Reading: Page 221
Industry reads hand-picked by our editors
Sep 25, 2019
-
Vantage
Does amount matter when it comes to a biotech IPO?
-
The Washington Post
Why the cancer ‘moonshot’ has been so disappointing
-
The Wall Street Journal
A Big Biotech Bet Hiding in Plain Sight
Sep 24, 2019
Sep 23, 2019
-
CNN
Opioid-maker Purdue Pharma is allowed bonus payout in bankruptcy case
-
Endpoints
Genentech submits a big plan to expand its South San Francisco footprint
-
Financial Times
New allies fight Africa's deadly scourge of fake medicines
-
The Washington Post
As off-label use spreads for lifesaving niche drugs, supplies grow scarce, leaving patients in the lurch
Sep 20, 2019
-
Health Affairs
Understanding The House Democrats’ Drug Pricing Package
-
The Wall Street Journal
You've survived cancer. What comes next?
-
Associated Press
Will combo pill catch on in US to prevent heart attacks?
-
Bloomberg
The New Capitalism Is Looking a Lot Like the Old Capitalism
Sep 19, 2019
Sep 18, 2019
-
STAT
'Reasonable' pricing could limit the cost for Zolgensma in France
-
Science
A new sickle cell drug could soon get U.S. approval. But does it work?
-
Reuters
U.S. Senators urge FTC to scrutinize multi-billion dollar pharma mergers
-
S&P
'Right to Try' twin startups, Trump's claims stir confusion, bioethicists say
Sep 17, 2019
-
The Wall Street Journal
Purdue Pharma Looks to Extend Bankruptcy Shield to Sacklers
-
Reuters
With a backup to the backup, insulin makers say they're primed for Brexit
-
San Francisco Business Times
A look inside Merck's new Peninsula research 'superhub'
-
The Columbus Dispatch
Former Dublin couple accused of stealing Nationwide Children's trade secrets
Previous
